IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)
$5.57 0 (0%)
Analysed IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) News Sources
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
14-04-2026
marketbeat.com
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
06-04-2026
yahoo.com
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
17-03-2026
yahoo.com
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
09-03-2026
247wallst.com
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
06-03-2026
yahoo.com
Immuneering to Present at the Leerink Global Healthcare Conference
02-03-2026
yahoo.com
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3
28-02-2026
marketbeat.com
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
18-02-2026
yahoo.com
Director of Immuneering Picks Up 1.8% More Stock
16-01-2026
yahoo.com
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition
11-01-2026
yahoo.com
What is the current price of IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)?
The current price of IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) is $5.57.
IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) since the previous trading day is $0.
IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)?
The most recent average sentiment score for IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)?
The most recent sentiment for IMMUNEERING CORP - CLASS A (IMRX:NASDAQ) is .
SEC-8K** Filing Available For IMMUNEERING CORP - CLASS A (IMRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.